Pharmaceutical Business Review
Anonymous User | Login

Regeneron initiates enrollment in Phase III gout program

Published: 02-Apr-2009

Arcalyst approved in the US for the treatment of cryopyrin-associated periodic syndromes

Regeneron Pharmaceuticals, a biopharmaceutical company, has initiated patient enrollment in the Phase III program evaluating the efficacy and safety of Arcalyst, also known as interleukin-1 trap, in the prevention of gout flares associated with the initiation of urate-lowering drug therapy and in the treatment of acute gout attacks.

This Phase III program with Arcalyst in gout was designed following discussions with the FDA. It will consist of four clinical studies. The North American-based Pre-Surge 1 study and the global Pre-Surge 2 study are each evaluating the number of gout flares per patient over the first 16 weeks of initiation of allopurinol therapy.

The global Surge study in patients experiencing an acute gout attack is evaluating pain during the initial 72 hours of treatment.

Arcalyst is approved in the US for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome in adults and children 12 and older.

George Yancopoulos, president of Regeneron Research Laboratories, said: This comprehensive Phase III program reflects our enthusiasm for the potential role of Arcalyst therapy in these two gout patient populations. Initial data from this program are expected in 2010.

Mail sent successfully

Tell your friend about this article


Please enter a valid email address

Please enter your name

Please enter the mail body


Your Name: *
Your Email: *
Friend's Email: *
Email Body: *
 

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

BaseCon

IT Pharma Solutions ...

ETS Nederland BV

(Experimental Toxicology Services) ...

TNO

Pharma Services: From Discovery to the Clinic ...

Fraunhofer ITEM

Human Health Research ...

Anoto

Providing Unique Technology for Digital Pen and Paper ...

ProtNeteomix

Developing Applications for Drug Discovery & Development and Diagnostics ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

CaseBase Management

BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...

SafetyBase Interchange

BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...

ClinicalBase Trial

BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...

Reliable Prediction of White Plasma Levels

Our kinetics & metabolism experts can help you select and further develop your candidate d ...

Kinetics and Metabolism

Our kinetics & metabolism experts can help you select and further develop your candidate d ...

Drug Safety Evaluation

Our kinetics & metabolism experts can help you select and further develop your candidate d ...

Related Companies

No items to display

Suppliers Product News

Amarna Therapeutics B.V. and TNO Announce SVac Research and Development Partnership

Dutch biotechnology company Amarna Therapeutics B.V. and the Netherlands Organisation for Applied Scientific Research TNO today announced that they have entered into a collaboration agreement to further develop Amarna's viral gene delivery platform SVac.

Organisations Throwing Mobile Technology at Problems With Little Consideration of Actual User and Business Needs, Quocirca

Survey reveals detrimental impact on organisational effectiveness and IT expenditure in healthcare and finance across the UK, France, Germany and the US.

Digital Pen and Paper Technology Helps Accelerate Clinical Trials

Digital pen and paper technology captures handwritten clinical data electronically, quickly and securely to save time and cost in drug discovery process.

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750

Please enter a valid email address